Regulation of the Ets-1 transcription factor by sumoylation and ubiquitinylation

Sumoylation and ubiquitinylation reversibly regulate the activity of transcription factors through covalent attachment to lysine residues of target proteins. We examined whether the Ets-1 transcription factor is modified by sumoylation and/or ubiquitinylation. Among four potential SUMO motifs in Ets-1, we identified lysines 15 and 227 within the LK15YE and IK227QE motifs, as being the sumoylation acceptor sites. Using transfection of Ets-1 wildtype (WT) or its sumoylation deficient version (Ets-1 K15R/K227R), as well as WT or mutant proteins of the SUMO pathway, we further demonstrated that the E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation, while a SUMO protease, SENP1, can desumoylate Ets-1. We also found that Ets-1 is modified by K48-linked polyubiquitinylation independently of the sumoylation acceptor sites and is degraded through the 26S proteasome pathway, while sumoylation of Ets-1 does not affect its stability. Finally, sumoylation of Ets-1 leads to reduced transactivation and we demonstrated that previously identified critical lysine residues in Synergistic Control motifs are the sumoylation acceptor sites of Ets-1. These data show that Ets-1 can be modified by sumoylation and/or ubiquitinylation, with sumoylation repressing transcriptional activity of Ets-1 and having no clear antagonistic action on the ubiquitin-proteasome degradation pathway.

[1]  Zhengxin Wang,et al.  SENP1 Enhances Androgen Receptor-Dependent Transcription through Desumoylation of Histone Deacetylase 1 , 2004, Molecular and Cellular Biology.

[2]  F. J. Herrera,et al.  Molecular Biology: What Ubiquitin Can Do for Transcription , 2004, Current Biology.

[3]  B. Vandenbunder,et al.  The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering. , 1999, Molecular biology of the cell.

[4]  L. McIntosh,et al.  Structure of the Ets-1 pointed domain and mitogen-activated protein kinase phosphorylation site. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  N. Muthusamy,et al.  Defective activation and survival of T cells lacking the Ets-1 transcription factor , 1995, Nature.

[6]  B. Wasylyk,et al.  Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2 , 1997, Oncogene.

[7]  R. Hay,et al.  SUMO-1 Conjugation in Vivo Requires Both a Consensus Modification Motif and Nuclear Targeting* , 2001, The Journal of Biological Chemistry.

[8]  G. Blobel,et al.  A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex , 1996, The Journal of cell biology.

[9]  R. Hay,et al.  Ubch9 conjugates SUMO but not ubiquitin , 1997, FEBS letters.

[10]  J. Iñiguez-Lluhí,et al.  A Common Motif within the Negative Regulatory Regions of Multiple Factors Inhibits Their Transcriptional Synergy , 2000, Molecular and Cellular Biology.

[11]  A. Ciechanover,et al.  The ubiquitin system. , 1998, Annual review of biochemistry.

[12]  R. Hay,et al.  SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. , 1998, Molecular cell.

[13]  Erica S. Johnson,et al.  Protein modification by SUMO. , 2004, Annual review of biochemistry.

[14]  Toshiyuki Yamada,et al.  Molecular biology of the Ets family of transcription factors. , 2003, Gene.

[15]  T. Saruta,et al.  Ubc9 and Protein Inhibitor of Activated STAT 1 Activate Chicken Ovalbumin Upstream Promoter-Transcription Factor I-mediated Human CYP11B2 Gene Transcription* , 2005, Journal of Biological Chemistry.

[16]  A. Dejean,et al.  Nuclear and unclear functions of SUMO , 2003, Nature Reviews Molecular Cell Biology.

[17]  B. Vandenbunder,et al.  Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway , 2002, Oncogene.

[18]  Min Wang,et al.  The Small Ubiquitin-like Modifier-1 (SUMO-1) Consensus Sequence Mediates Ubc9 Binding and Is Essential for SUMO-1 Modification* , 2001, The Journal of Biological Chemistry.

[19]  R. Sood,et al.  Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell-cycle-dependent assembly into nuclear bodies. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Jürgen Dittmer,et al.  Molecular Cancer BioMed Central Review The Biology of the Ets1 Proto-Oncogene , 2003 .

[21]  A. Dejean,et al.  FLI-1 Functionally Interacts with PIASxα, a Member of the PIAS E3 SUMO Ligase Family* , 2005, Journal of Biological Chemistry.

[22]  S. Müller,et al.  SUMO: a regulator of gene expression and genome integrity , 2004, Oncogene.

[23]  F. Alt,et al.  Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene , 1995, Nature.

[24]  B. Wasylyk,et al.  Modulation of ETS-1 transcriptional activity by huUBC9, a ubiquitin-conjugating enzyme , 1997, Oncogene.

[25]  Y. De Launoit,et al.  Inhibition of JNK by HGF/SF Prevents Apoptosis Induced by TNF‐α , 2003, Annals of the New York Academy of Sciences.

[26]  B. Wasylyk,et al.  Sumoylation of the net inhibitory domain (NID) is stimulated by PIAS1 and has a negative effect on the transcriptional activity of Net , 2005, Oncogene.

[27]  R. Dohmen SUMO protein modification. , 2004, Biochimica et biophysica acta.

[28]  S. Müller,et al.  PIAS/SUMO: new partners in transcriptional regulation , 2003, Cellular and Molecular Life Sciences CMLS.

[29]  D. Glossip,et al.  Sumoylation of LIN-1 promotes transcriptional repression and inhibition of vulval cell fates , 2005, Development.

[30]  P. Mehlen,et al.  Proapoptotic Function of the MET Tyrosine Kinase Receptor through Caspase Cleavage , 2004, Molecular and Cellular Biology.

[31]  Y. Totsuka,et al.  E1AF degradation by a ubiquitin-proteasome pathway. , 2005, Biochemical and biophysical research communications.

[32]  G. Blobel,et al.  Ubc9p Is the Conjugating Enzyme for the Ubiquitin-like Protein Smt3p* , 1997, The Journal of Biological Chemistry.

[33]  L. McIntosh,et al.  Solution structure of the ETS domain from murine Ets‐1: a winged helix‐turn‐helix DNA binding motif. , 1996, The EMBO journal.

[34]  M. Crossley,et al.  Role for SUMO Modification in Facilitating Transcriptional Repression by BKLF , 2005, Molecular and Cellular Biology.

[35]  K. Bohren,et al.  A M55V Polymorphism in a Novel SUMO Gene (SUMO-4) Differentially Activates Heat Shock Transcription Factors and Is Associated with Susceptibility to Type I Diabetes Mellitus* , 2004, Journal of Biological Chemistry.

[36]  A. Sharrocks,et al.  PIASx acts as an Elk‐1 coactivator by facilitating derepression , 2005, The EMBO journal.

[37]  J. Baert,et al.  The transcription of the intercellular adhesion molecule-1 is regulated by Ets transcription factors , 1998, Oncogene.

[38]  H. Saitoh,et al.  Functional Heterogeneity of Small Ubiquitin-related Protein Modifiers SUMO-1 versus SUMO-2/3* , 2000, The Journal of Biological Chemistry.

[39]  G. V. Vande Woude,et al.  Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Ivan Dikic,et al.  Ubiquitylation and cell signaling , 2005, The EMBO journal.

[41]  R. Hay,et al.  SUMO: a history of modification. , 2005, Molecular cell.

[42]  D. Monté,et al.  SUMO Modification of the Ets-related Transcription Factor ERM Inhibits Its Transcriptional Activity* , 2005, Journal of Biological Chemistry.

[43]  Andrew D Sharrocks,et al.  Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. , 2003, Molecular cell.

[44]  Boris Pfander,et al.  RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO , 2002, Nature.